Last year, the company moved into new space in Woburn, MA to double the capacity of its prior Cambridge facility.
Having provided characterization services for 10 of the top biosimilar products in development, Blue Stream offers a complete suite of analytical solutions for biosimilar product development from initial product screening to biosimilar/originator comparability to comprehensive characterization including primary and secondary/tertiary structure, glycosylation/PTMs, and activity.
The biosimilar segment continues to perform well for the company. In 2014, Blue Stream recorded a 60% increase in revenue over the prior year, along with a 50% increase in facility size, and a 30% expansion of its research and development capabilities.
“The market for biosimilars continues to grow, with consensus of reaching at least $20 billion within the next few years. Blue Stream has significant biosimilar expertise, and we continue to invest in the people, equipment and infrastructure to develop innovative methods, improve quality and extend our expertise,” said William Rash, vice president, sales and marketing, Blue Stream Laboratories.
